Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
BioCryst Pharmaceuticals, Inc.'s quarterly P/E stands at 1.7x.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 7.23 | 1.74 | 32.33 | 112.00 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.13 | 1.05 | 2.62 | 3.02 | 2.77 | 2.96 | 3.36 | 2.92 | 2.82 | 3.23 | 3.87 | 4.03 | 5.71 |
| — | -64.5% | -22.0% | +3.4% | -1.7% | -8.2% | -13.2% | -27.7% | -50.6% | -52.1% | -50.0% | -46.1% | -62.0% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 5.37 | 0.95 | 10.49 | 11.98 | — | — | 48.02 | — | — | — | — | — | — |
| — | — | -78.2% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 5.24 | 1.57 | 18.95 | 21.46 | 27.12 | — | 72.38 | 55.58 | — | — | — | — | — |
| — | — | -73.8% | -61.4% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 5.24 | — | 17.83 | 23.03 | 24.10 | — | 50.90 | 41.27 | — | — | — | — | — |
| — | — | -65.0% | -44.2% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
BioCryst Pharmaceuticals, Inc.'s operating margin was 64.0% in Q4 2025, up 45.5 pp QoQ and up 67.5 pp YoY. This marks the 5th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 28.9% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.8% | 97.7% | 98.4% | 98.3% | 96.9% | 95.3% | 97.2% | 98.4% | 98.6% | 98.2% | 98.7% | 98.8% | 98.6% |
| — | +2.4% | +1.2% | -0.2% | -1.8% | -3.0% | -1.5% | -0.4% | +0.0% | +1.4% | +3.6% | -0.8% | -0.9% | |
| Operating Margin | 39.0% | 64.0% | 18.6% | 18.2% | 14.6% | -3.4% | 6.6% | 8.0% | -15.6% | -45.7% | -13.7% | -25.1% | -41.3% |
| — | +1968.7% | +182.6% | +127.6% | +193.4% | +92.5% | +147.8% | +131.9% | +62.2% | +21.5% | +40.3% | +52.6% | +58.7% | |
| Net Margin | 30.2% | 60.5% | 8.1% | 3.1% | 0.0% | -20.4% | -12.0% | -11.6% | -38.1% | -66.1% | -41.7% | -91.3% | -77.5% |
| — | +396.8% | +167.5% | +126.9% | +100.1% | +69.2% | +71.2% | +87.3% | +50.8% | +26.5% | +25.7% | -1.7% | +47.8% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | 52.5% | 51.2% | 2.9% | 1.1% | 0.0% | -5.5% | -2.9% | -2.7% | -7.2% | -11.9% | -6.9% | -14.5% | -10.1% |
| — | +1037.7% | +198.0% | +140.3% | +100.1% | +54.0% | +57.6% | +81.4% | +28.6% | +8.0% | +13.7% | -27.8% | +24.3% | |
| ROIC | 807.9% | 2811.1% | 11.0% | 9.6% | 6.0% | -1.3% | 2.1% | 2.5% | -4.1% | -11.8% | -3.1% | -5.5% | -10.3% |
| — | +223134.2% | +416.7% | +290.1% | +244.6% | +89.3% | +168.4% | +144.7% | +59.8% | +36.4% | +44.9% | — | +95.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
BioCryst Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.0x, down from 22.8x last quarter — comfortably within a safe range. The current ratio has weakened 21.6% YoY to 2.06x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 0.03 | 0.04 | 22.83 | 23.35 | 38.47 | — | 105.23 | 90.48 | — | — | — | — | — |
| — | — | -78.3% | -74.2% | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.06 | 2.06 | 1.87 | 2.25 | 2.93 | 2.63 | 2.78 | 2.82 | 3.73 | 3.31 | 5.54 | 5.47 | 5.76 |
| — | -21.6% | -32.8% | -20.1% | -21.4% | -20.4% | -49.8% | -48.5% | -35.3% | -32.4% | -11.2% | +5.4% | -8.7% | |
| Quick Ratio | 2.03 | 2.03 | 1.84 | 2.22 | 2.88 | 2.58 | 2.73 | 2.78 | 3.48 | 3.12 | 5.21 | 5.18 | 5.44 |
| — | -21.2% | -32.6% | -20.2% | -17.2% | -17.2% | -47.6% | -46.3% | -36.1% | -32.8% | -11.8% | +4.7% | -11.0% | |
| Interest Coverage | — | — | 1.51 | 1.38 | 0.90 | -0.18 | 0.31 | 0.35 | -0.59 | -1.74 | -0.44 | -0.72 | -1.04 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonBioCryst Pharmaceuticals, Inc.'s current P/E is 7.2x. The average P/E over the last 3 quarters is 48.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioCryst Pharmaceuticals, Inc.'s current operating margin is 39.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioCryst Pharmaceuticals, Inc.'s business trajectory between earnings reports.